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Dendritic cells (DCs) play a key role in orchestrating
adaptive immune responses. In human blood, three
distinct subsets exist: plasmacytoid DCs (pDCs) and
BDCA3+ and CD1c+ myeloid DCs. In addition, a DC-
like CD16+ monocyte has been reported. Although
RNA-expression profiles have been previously
compared, protein expression data may provide a
different picture. Here, we exploited label-free quanti-
tativemass spectrometry to compare and identify dif-
ferences in primary humanDC subset proteins. More-
over,we integrated theseproteomicdatawithexisting
mRNA data to derive robust cell-specific expression
signatureswithmore than400differentially expressed
proteins between subsets, forming a solid basis for
investigation of subset-specific functions. We illus-
trated this by extracting subset identificationmarkers
and by demonstrating that pDCs lack caspase-1 and
only express low levels of other inflammasome-
relatedproteins. In accordance, pDCswere incapable
of interleukin (IL)-1b secretion in response to ATP.
INTRODUCTION
Dendritic cells (DCs) play a critical role in the initiation of antigen-
specific adaptive immune responses to foreign antigens and theCell Report
This is an open access article under the CC BY-Nmaintenance of tolerance to self-antigens (reviewed by Balan
et al., 2014; Reynolds and Haniffa, 2015; Vu Manh et al., 2015).
DCs harbor the unique capacity to process and present antigens
complexed to either major histocompatibility complex (MHC)
class I or MHC class II and thereby can activate naive T cells.
It is because of this ability that DCs have become of interest
as tools or targets for cancer immunotherapy to initiate or boost
tumor immunity.
Several DC subsets can be distinguished that differ in their
ability to sense and respond to pathogens and in the type of im-
mune response they initiate. Two main types of naturally occur-
ring blood DCs have been characterized: plasmacytoid DCs
(pDCs) and myeloid DCs (mDCs) (reviewed by Vu Manh et al.,
2015). pDCs play a key role in antiviral immunity, through their
ability to produce large amounts of type I interferons (IFNs).
mDCs represent the ‘‘traditional’’ antigen-presenting DCs that
can be further subdivided based on the expression of BDCA3
(CD141) and CD1c (BDCA1). Each can be defined through the
expression of different pattern recognition receptors (PRRs;
e.g., Toll-like receptors [TLRs] and C-type lectin receptors
[CLRs]) and the secretion of a distinct set of cytokines upon stim-
ulation (reviewed by Balan et al., 2014; Reynolds and Haniffa,
2015; Vu Manh et al., 2015). Whereas CD1c+ mDCs express
most TLRs, except TLR9, BDCA3+ mDCs express mainly
TLR3. Furthermore, BDCA3+ mDCs express the CLR CLEC9a,
which facilitates the uptake of dying cells and subsequent
cross-presentation of derived antigens to T cells (Ahrens et al.,
2012; Jongbloed et al., 2010; Poulin et al., 2010). Finally,
although not considered a genuine DC, a CD16+ subset ofs 16, 2953–2966, September 13, 2016 ª 2016 The Author(s). 2953
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
monocytes, coined ‘‘non-classical monocytes,’’ can be found in
blood with DC-like properties (Ziegler-Heitbrock et al., 2010). So
far, these DCs subsets have been mostly characterized and iso-
lated based on cell-specific (surface) markers and functionally
compared for abilities such as antigen presentation, cytokine
secretion, and migration (Balan et al., 2014; Reynolds and Ha-
niffa, 2015; Vu Manh et al., 2015). These functional assays, how-
ever, can be biased as they provide information on only a few a
priori determined functional responses to a limited set of activa-
tion stimuli and antigens. Although highly valuable in investi-
gating the abilities of each subset under specific circumstances,
these assays may leave more untraditional unique characteris-
tics of each subset undetected. To overcome this, unbiased an-
alyses of mRNA expression of human and mouse DC subsets
have been performed and proven to be highly informative (Lind-
stedt et al., 2005; Manh et al., 2013; Miller et al., 2012; Robbins
et al., 2008). Comparative transcriptome analysis delivered the
most compelling evidence for the current thought that the human
BDCA3+ mDC is the counterpart of the murine CD8a+ DC,
despite the lack of conservation of identification markers (Rob-
bins et al., 2008). In addition, the Robbins et al. (2008) study
demonstrated that the CD16+ DC-like cell, based on its full tran-
scriptional program, resembles a monocyte more than a DC.
Although these studies have provided valuable insight into the
relation between DC subsets in mice and humans, RNA expres-
sion does not always reflect protein expression. Since not all
RNA is translated, RNA and proteins may have dissimilar half-
lives and kinetics, and protein levels may also be regulated by
post-transcriptional modifications. Furthermore transcriptomics
does not take into account pre-existing protein levels, alterations
in translation efficiency, or protein stability. Therefore, transcrip-
tome expression data may have limited predictive power on
which proteins really define each DC subset and may have left
important phenotypic and functional differences unnoticed. To
confirm and supplement the existing transcriptome analysis,
we have performed a comprehensive mass-spectrometry
(MS)-based quantitative proteome comparison of rare blood
DC subsets. Furthermore, we integrated protein and RNA data
to derive expression signatures that give a more reliable and
comprehensive account of expression differences than can be
achieved from using either technique alone. The expression
signatures represent an easily accessible resource to derive
hypotheses on subset-specific functions. To illustrate this, we
validated five of the identified differentially expressed surface
markers and showed that caspase-1 is completely lacking in
pDCs, which is accompanied by restricted expression of other
inflammasome components and affects the function of these
cells.
RESULTS
Quantitative Proteomics of Primary Human DC Subsets
For proteome characterization, four DC-(like) subsets (i.e., pDCs,
CD1c+ mDCs, BDCA3+ mDCs, and CD16+ monocytes) were
isolated from apheresis products obtained from healthy volun-
teers by magnetic-bead-based cell separation. The purity of
the isolated cells and presence of cross-contamination were as-
sessed by flow cytometry (Figure S1). For pDCs, CD1c+ mDCs,2954 Cell Reports 16, 2953–2966, September 13, 2016and CD16+ monocytes, high purity (R95%) was obtained for all
subsets without major cross-contamination or presence of B or
T cells in two out of three donors. For a third donor, medium-
high purity was obtained (78%–92%). For BDCA3+ mDC
samples, most cells were BDCA3+CD11c+ (87%–95%). We
observed however, a variable number of CD11c+ cells express-
ing intermediate levels of BDCA3 (BDCA3int) in the isolate
together with cells positive for CD1c+, indicating cross-contam-
ination of this sample with CD11c+CD1c+BDCA3int cells. There-
fore, we consider these samples to be BDCA3+ mDC enriched
rather than pure. Nevertheless, we reasoned that this sample is
still of use to derive BDCA3+ mDC-specific protein expression,
which may be achieved by relating the BDCA3+ mDC-enriched
samples to the (BDCA3+-depleted) CD1c+ mDC samples. All
12 (three donors times four subsets) samples were, first, each
separated using SDS-PAGE, fractionated into 20 fractions, and
subjected to in-gel trypsin digestion (yielding 240 fractions in
total). The fractions were measured in triplicate, using highly
sensitive liquid chromatography-tandem MS (LC-MS/MS) for
maximal protein coverage. After peptide identification and
sequence alignment, proteins were quantified using the label-
free quantification (LFQ) algorithm in MaxQuant (Cox et al.,
2014). The Pearson correlation was very high (r = 0.97 ± 0.02) be-
tween technical replicates and high (r = 0.93 ± 0.02) between bio-
logical replicates (e.g., the same subsets from different donors),
indicating good reproducibility across measurements and do-
nors (Table S1). In total, we identified 42,723 non-redundant
peptide sequences corresponding to 4,196 protein groups
(Table S2; Table S3). Requiring a protein to be expressed in at
least two donors for each subset, we identified 2,351, 2,197,
2,009, and 1,883 proteins in pDCs, BDCA3+ mDCs, CD1c+
mDCs, and CD16+ cells, respectively, and 2,823 proteins overall
(Figures S2A–S2D; Tables S2 and S3). Next, using the CORUM
database of protein complexes, we inspected the identification
of components of protein complexes essential for cell homeo-
stasis (e.g., mitochondrial complexes and proteasomes), to
assess the completeness of the proteome in each cell type
(Luber et al., 2010). We recovered most components, indicating
that our proteome covered the majority of DC proteins (Fig-
ure S2E). Coverage was best in pDCs and BDCA3+ mDCs,
yielding 70%–100% of essential protein complexes, and was
least in CD16+ cells (40%–100%; Figure S2E).
We then evaluated the assignment of key identification
markers for each subset. No markers specific for other major
leukocyte populations (e.g., T, B, or NK cells) were identified,
suggesting a lack of substantial contamination with other leuko-
cytes. In contrast, we readily identified the unique expression of
at least one previously reported subset-specific protein for each
subset, including TLR7, TLR9, CLEC4C, NRP1, and IL3RA for
pDCs; IDO and HLA-DO for BDCA3+ mDCs; and CD16
(FCGR3A) for CD16+ monocytes (Table 1). Importantly, CD1c
was uniquely detected in CD1c+ mDCs but not in BDCA3+
mDCs. For BDCA3+ DCs, we did not immediately identify
more traditional markers such as BDCA3 (CD141, THBD),
CLEC9a, TLR3, NECL2, and XCR1 using the default peptide
identification threshold (false discovery rate [FDR] = 0.01).
Possibly, this was due to a low expression, high hydrophobicity,
or heavy glycosylation of these molecules. Nevertheless, we
Table 1. Subset Identification Markers Uniquely Identified
Peptides
D1 D2 D3
pDCs
TLR9 5 10 11
IL3RA (CD123) 2 3 7
CLEC4C (BDCA2) 0 2 4
TLR7 0 4 7
NRP1 (BDCA4) 1 0 1
CD1c+
CD1C 2 2 2
BDCA3+
IDO1 8 5 10
TLR3 3 0 0
THBDa (BDCA3) 1 0 2
CLEC9Aa 0 1 0
CD16+
FCGR3A (CD16) 3 3 3
Shown here are the numbers of peptides identified and quantified
for each marker protein for each subset. Shown markers were uniquely
identified in the indicated subset.
aPeptides were detected by releasing the FDR threshold of 0.01, and
spectra were manually validated.found a unique expression of IDO and HLA-DO in BDCA3+
mDCs; they were previously reported to be highly expressed
in especially this subset (Crozat et al., 2010; Hornell et al.,
2006). Upon more close inspection of peptides, however, TLR3
was found in one BDCA3+ mDC sample, and CLEC9A and
BDCA3 (CD141/THBD) were found in two samples. Because
these peptides were detected with low confidence (FDR = 1),
we generated MS/MS spectra and manually verified this result
(data not shown). Together, the expression patterns of estab-
lished marker proteins demonstrate the ability of our approach
to discern the distinct identity of each subset.
We also obtained quantitative information using the LFQ algo-
rithm in MaxQuant (Cox et al., 2014). First, we used this informa-
tion to compare protein expression in the three main populations
of blood DC-like cells (i.e., pDCs, CD1c+ mDCs, and CD16+
monocytes), excluding the BDCA3+ mDC samples. We calcu-
lated average expression differences between any two subsets
and visualized these in volcano plots (Figure 1A; see Table S4
for complete statistical analysis). It should be noted that here
and in the remainder of the manuscript, only proteins expressed
in at least two donors in one of the cell types being compared are
included. Pairwise comparisons further highlighted subset iden-
tity, showing specific expression of CD11c (ITGAX/ITGB2) in
myeloid cells and overexpression in the pDCs of several proteins
with a reported pDC-specific expression and function (e.g.,
PACSIN1, SLC15A4, IRF7, TCF4, BCL11A, BLNK, and CD2AP)
(Blasius et al., 2010; Cisse et al., 2008; Crozat et al., 2010; Esashi
et al., 2012; Marafioti et al., 2008; Robbins et al., 2008; Ro¨ck
et al., 2007; Wu et al., 2013).
Next, we determined the relation between cell types by hierar-
chical clustering (Figure 1B). Based on all proteins, subsets clus-tered together mostly on cell type rather than on donor. Further-
more, CD16+monocytes and CD1c+mDCs that share amyeloid
origin were closer to each other than to pDCs. Hierarchical clus-
tering of samples based on 1,218 differentially expressed pro-
teins (DEPs) between the three subsets showed a separation
similar to that seen when using all proteins and indicated six
main groups of DEPs that showed higher or lower expression
in one of the three subsets (Figure 1C). Next, we assessed how
our protein data related to mRNA data. We merged our protein
data with a previously published and publicly available microar-
ray dataset of the same subsets (Lindstedt et al., 2005). For one
of the donors that was used for MS analysis, we also acquired
sufficient material to perform RNA sequencing on the same sam-
ple (Table S5). We first assessed the overall correlation between
microarray-derived RNA data and proteome data for each cell
type and found this to be low, similar to our previous observa-
tions (Figure 1D; r = 0.28–0.31) (Buschow et al., 2010). The cor-
relation between RNA-sequencing data and proteome data for
the matched donor was slightly better (0.37–0.45). Cross-corre-
lation of this RNA-sequencing dataset to the protein data of the
two other donors, however, produced a similar correlation,
indicating that the different RNA analysis method was mostly
responsible for the improved correlation (Table S6). To make a
more in-depth comparison of the RNA data to our proteome da-
taset possible, we transformed both microarray-derived RNA
and protein expression data to relative expression levels for
each dataset separately (Z scores, mean to 0, variance to 1).
From the merged dataset, we yielded 742 DEPs for which also
RNA data were available. Again, we used the merged RNA and
protein data for these 742 DEPs as input for hierarchical clus-
tering (Figure 1E; Table S6). The combined protein and RNA
samples grouped the distinct subsets from the two datasets
together, indicating that, despite moderate correlation between
absolute expression levels, there was a good correlation be-
tween RNA and protein expression patterns (Figure 1E). Impor-
tantly, the clustering was determined neither by biological varia-
tion between donors nor by technical variation between omics
technologies.
Generation of Protein-Based Expression Signatures and
Networks
Protein and RNA data were not consistent in all cases, and pro-
teome analysis put forward DEPs for which differences at the
RNA level were only minor or for which no probes had been pre-
sent on the microarray chips. Next, we set out to visualize were
exactly proteome analysis pointed to not previously appreciated
differences between DC subsets and the cases in which RNA
and protein were in agreement. For the six groups of DEPs asso-
ciated with the three subsets (Figure 1C), we generated protein
expression signatures based on four different evidence levels:
(I) subset-specific protein expression/absence, supported by
RNA data; (II) differential protein expression between subsets,
supported by RNA data; (III) subset-specific protein expres-
sion/absence, not supported by RNA data; and (IV) differential
protein expression between subset, not supported by RNA
data (Figure 2; Supplemental Experimental Procedures). Pro-
teins included in signatures based on level I and level II evidence
behaved consistently in RNA and protein datasets. Thus, theseCell Reports 16, 2953–2966, September 13, 2016 2955
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Figure 1. Comparison of Protein Expression between Three Main Blood DC-like Subsets and Integration with RNA Data
(A) Volcano plots depicting protein expression differences (x axis: log2 fold change) and the significance level (y axis:log10 t test p value). Colored dots represent
proteins with a fold change of >2 and p < 0.05; proteins in gray did not meet these criteria. Proteins specific to one of the two subsets compared were assigned a
fold change of infinity. See also Table S4.
(B) Unsupervised hierarchical clustering of DC subsets using all proteins (1  Pearson correlation).
(C) Clustering of subsets based on 1,218 DEPs (based on three-group one-way ANOVA, p < 0.05, or specific expression).
(D) Pearson correlation between protein and RNA (microarray) expression levels.
(E) Hierarchical clustering of merged transcriptome and proteome data (DEPs only).
See also Figures S1 and S2 and Tables S1, S2, S3, S4, S5, and S6.
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proteins are, thus, likely mostly regulated at the transcriptional
level. Importantly, for these proteins, proteomics data confirmed
RNA-identified differences between subsets. Many established
markers were present in these two groups: e.g., IL3RA, CLEC4C,
TLR9, CD1c, and FCGR3B (CD16). Supported by two lines of
evidence, other proteins in these groups now represent high-
potential subset identification markers and include CD163 for
CD1c+ mDCs and SIGLEC10 for CD16+ monocytes (Figure 2;
Table S7). In contrast, proteins included in signatures based on
level III and level IV evidence reflect less consistency between
protein and RNA expression patterns or a lack of transcriptional
information/ChIP (chromatin immunoprecipitation) annotation.
Proteins in these evidence groups represent the added value
of the proteome analysis (Figure 2). Finally, proteins that were
put forward as differentially expressed by RNAdata (differentially
expressed genes; DEGs), and that were also present in our pro-
tein dataset but were not confirmed as differentially expressed
by proteomics, are listed in Table S8.
Together, we confirmed differential or unique expression of
253 proteins between the three subsets previously observed
by RNA expression (pDCs, 109 higher/65 lower; CD1c+ mDCs,
17 higher/1 lower; CD16+ monocytes, 34 higher/27 lower) that
could also be derived from the transcriptome data (levels I
and II; Figure 3; Table S7, including lower confidence DEPs).
In addition, 143 proteins were found to be differently/uniquely
expressed between subsets based on proteomics data only
(levels III and IV), which hold yet-unappreciated differences be-
tween DC subsets (pDCs, 75 higher/14 lower; CD1c+ mDCs,
10 higher/8 lower; CD16+ monocytes, 10 higher/26 lower).
To obtain insight into the overall function of signature proteins,
we performed a protein-protein interaction (PPI) analysis and
a functional annotation (FA) analysis (Figure 3; Table S9). PPI
analysis demonstrated good connectivity between proteins
high in pDCs (0.73 connection per protein), proteins low in
pDCs (1 connection per protein), those high in CD1c+ mDCs
(0.85 connection per protein), and those low in CD16+ mono-
cytes (0.64 connection per protein) (Figure 3; Table S9). Much
less connectivity was found between proteins high in CD16+
monocytes (0.25 connection per protein) and those low in
CD1c+ mDCs (no connections were identified).
In the CD1c+mDC high signature, the MCM family and acces-
sory proteins that regulate the cell cycle were found by proteome
analysis only and were highly connected, suggesting a unique
role for this complex in CD1c+ mDCs (Figure 3; Table S9). This
complex was completely absent fromCD16+monocytes. Prote-
ome analysis, but not RNA analysis, also pointed out that CD1c+
mDCsmore highly expressed both the alpha-chain and the beta-
chain of HLA-DQ, which may, thus, be of specific importance in
this DC subset. The largest gene signatures were obtained for
pDCs and mostly mapped to expected pDC functions, including
TLR and IFN signaling (e.g., TLR9, IRF7, IRF8, andSMAD3), butFigure 2. Cell-Specific Gene Signatures Derived from Proteomics and
(A–F) Protein-based gene signatures for higher or lower expression in the three m
four evidence levels: (I) specific protein expression/absence with RNA suppo
expression without RNA support; and (IV) differential protein expression without R
two donors only but were included because of RNA support (e.g., ‘‘rescued’’). The
and donor. See also Table S7.
2958 Cell Reports 16, 2953–2966, September 13, 2016also to endoplasmic reticulum (ER), Golgi, and vesicular trans-
port, indicating high protein biosynthesis in this cell type
(e.g., SEC24A, SEC31A, SEC11C, PDIA5, PDIA4, ERGIC3, and
LMAN1) (Figure 3; Table S9). Intriguingly, IFN and TLR signaling
pathway constituents were highly expressed in pDCs by both
RNA and protein analyses, while proteins involved in protein
biosynthesis and vesicular transport were, in many cases, highly
expressed at the protein level only (Figure 3). The proteins absent
from pDCs (e.g., shared by CD1c+ mDCs and CD16+ mono-
cytes) were also highly connected and related to cell adhesion
and protrusion formation (e.g., ZYX, MSN, PAK1, VASP, and
FSCN1; Table S9), in line with the rounder non-adhesive pheno-
type of pDCs. Furthermore, pDCs hardly expressed or even
lacked TLR2, which detects bacterial lipoproteins, several
proteins connected to bactericidal endo/phagosomes (e.g.,
HMOX1, NCF2, and RAB27a) and CASP1 (caspase-1), a crucial
enzyme in the inflammasome-induced cleavage of interleukin
(IL)-1b in macrophages and DCs (Figure 3; Table S9).
BDCA3+ versus CD1c+ mDCs
Next, we investigated the difference between the two myeloid
DC subsets. Despite the presence of CD1c+ mDCs in the
BDCA3+ mDC samples, mDC samples were largely devoid of
other blood cells (Figure S1). Importantly, CD1c+ mDC samples
were devoid of BDCA3+ mDCs. A direct comparison between
the two sets of samples could, therefore, still reveal important
expression differences between mDC subsets (Figure 4; Table
S4). As expected, the number of DEPs between BDCA3+
mDCs and CD1c+ mDCs was much less than between other
subsets, reflecting the presence of CD1c+ cells in both samples
and/or their more common origin. Similar to what we found
before, protein only moderately correlated to RNA expression
(r = 0.31 formicroarray or r = 0.38 for RNA sequencing; Figure 4B;
Table S6). Despite the contamination with CD1c+ mDCs, the
BDCA3+ mDC protein samples clustered with the microarray
RNA samples of BDCA3+ mDCs, indicating that the cross-
contamination did not mask BDCA3+ mDC subset identity (Fig-
ure 4C). Finally, we derived DEPs between BDCA3+ mDCs and
CD1c+mDCs, using integration of protein andRNAdata (Figures
4D and 4E). DEPs included IDO1, FUCA1, CD93, HLA-DOB, and
TAP2 (high in BDCA3 mDCs) and also SIRPA, SIGLEC9, and
CASP1 (high in CD1c+ mDCs). Several more DEGs by microar-
ray showed a similar trend at the protein level but did not meet
our stringent criteria (e.g., IRF8, CAMK2D, and TAP1; Table
S8). Others were not found differentially expressed by prote-
omics or even showed an opposite trend.
Validation of DEPs
To demonstrate the resource value of our integrated proteome
and RNA analysis, we selected five cell-surface receptors for
validation. We chose cell-surface receptors because theseTranscriptomics
ain subsets derived from merged proteome and transcriptome data based on
rt; (II) differential protein expression with RNA support; (III) specific protein
NA support. Proteins marked by asterisks were specifically identified by MS in
heatmap colors represent relative protein expression (LFQ) in each DC subset
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may reflect the ability of each subset to recognize dangerous
agents, and could aid subset identification by flow cytometry.
Using the latter technique, we confirmed differential expression
of all five receptors: SIRPa and Siglec-9 were found on CD16+
monocytes and CD1c+ mDCs only; CD93 was especially high
on BDCA3+ mDCs; Siglec-10 was unique to CD16+ monocytes;
and, finally, CD163 was high on CD1c+ mDCs (Figure 5).
Absence of Caspase-1 in pDCs Reflects Low
Inflammasome Activity
Previous transcriptome analysis already indicated that pDCs
express lower levels of transcripts for proteins involved in anti-
bacterial innate immune responses (Crozat et al., 2009). It was
not clear whether this also translated to protein expression and
functionality. Our proteome data now confirm that pDCs express
lower levels of or lack TLR2, NAIP, HMOX, RAB27A, NCF2, and
CASP1 (Figure 2; Table S7). Caspase-1, a crucial player in
inflammasome function, was abundantly present in CD1c+
mDCs and CD16+ cells but was lacking in pDCs (Figure 6A).
In the BDCA3+ mDC-enriched sample, caspase-1 was present
but at much lower levels than in CD1c+ mDCs. Importantly, pro-
tein quantification was based on 6, 11, or even 13 peptides for
BDCA3+ mDCS, CD1c+ mDCs, or CD16+ monocytes, respec-
tively, while in pDCs, only a single peptide was mapped to cas-
pase-1 that was not adequate for quantification, suggesting the
absence or very low expression of this protein (Table S3). To
further substantiate these MS data, we analyzed protein expres-
sion by western blot (WB). Caspase-1 was readily detected in
CD1c+ mDCs and CD16+ monocytes but was present only at
very low levels in pure BDCA3+ mDCs and not at all detected
in pDCs (Figures 6B and S4). It should be noted that we did
detect low levels of caspase-1 in pDCs isolated by magnetic
beads but that protein expression was completely absent
when cells were sorted to high purity (>99%) by flow cytometry
(Figures 6 and S4). We next wondered whether pDCs would up-
regulate caspase-1 when activated. To test this, we incubated
cells with the TLR7/8 ligand R848. Cell activation by TLR stimu-
lation upregulated caspase-1 in CD1c+ mDCs but did not in
pDCs (Figures 6C and S4). CD16+ monocytes also did not
further increase caspase-1 expression upon TLR stimulation.
Upregulation of caspase-1 in BDCA3+ DCs could not be tested,
becausewe did notmanage to isolate a sufficient number of cells
to test both resting and stimulated conditions by WB.
Next, we were interested in the expression of other
components of the inflammasome pathway. Only very few other
proteins of this pathway were identified by MS: NAIP was also
detected in all subsets except for pDCs, while the inflamma-
some-component NLRC4 was identified in CD16+ monocytes
only (Figure 2; Table S7). Exploration of the publicly available
RNA expression data, however, indicated that low expression
in pDCs was not restricted to caspase-1 but also included
most other inflammasome components, as stated previously
(Crozat et al., 2009). CD16+ monocytes, in contrast, expressedFigure 3. Signature PPI Networks Highlight Functional Differences bet
(A–E) Signatures were used as input for STRING PPI analysis (confidence level, 0.
indicated in blue were included based on protein and RNA data, and red proteins
Table S7). Important biological functions of sections of each network are indicat
2960 Cell Reports 16, 2953–2966, September 13, 2016high levels of inflammasome constituents, CD1c+ mDCs ex-
pressed more moderate levels, and BDCA3+ mDCs expressed
low levels (Figure 6D). Together, these data strongly suggest
an overall low presence of inflammasome-related proteins in
pDCs. Consequently, pDCs may not be equipped to recognize
inflammasome-activating stimuli or to synthesize and secrete
IL-1b in response. All components of the pathway downstream
of ATP recognition were low in pDCs compared to the other sub-
sets (P2XR7, PANX, NLRP3, CARD8, PYCARD, and CASP1; Fig-
ure 6D), indicating that pDCsmay not be equipped to respond to
this danger-associated molecule. ATP can trigger the cleavage
and secretion of IL-1b, provided that necrosis factor kB (NF-
kB) signaling is present at the same time to induce pro-IL-1b
expression. As a proof of principle, we tested the ability of
subsets to secrete IL-1b in response to ATP, preceded by 4-hr
or overnight R848 stimulation to trigger NF-kB signaling via
TLR7/8. Upregulation of activation marker CD83 and/or produc-
tion of tumor necrosis factor a (TNF-a) was observed in all DC
subsets, demonstrating functional NF-kB signaling (Figures
6E–6G). IL-1b secretion was restricted to especially CD1c+
mDCs and CD16+ mDCs. Thus, these data confirm that
pDCs, indeed, lack IL-1b secretion in response to ATP. Of
note, IL-18, which also requires caspase-1 for secretion, was
readily secreted by ATP/R848-stimulated CD1c+ mDCs but
not by pDCs (Figure S4). BDCA3+ mDCs were clearly activated
by R848, as judged by the increased expression of CD83, yet
hardly produced any cytokines (including IL-1b) under these
circumstances (Figures 6E–6G).
These experiments together demonstrate that the inflamma-
some/caspase-1 pathway is present and functional in CD1c+
mDCs and CD16+ monocytes but not in pDCs. Concordantly,
pDCs do not secrete IL1b in response to ATP.
DISCUSSION
This study describes an elaborate proteome analysis of human-
blood-derived DC subsets and provides DC subset-specific pro-
tein signatures. This dataset holds unique information on the dif-
ferences between DC subsets and reveals which differences,
previously identified using mRNA, are really present at the pro-
tein level. Previously, Luber and colleagues analyzed the prote-
ome of murine DC subsets (Luber et al., 2010), but large-scale
proteomics of human DCs was thus far restricted to in-vitro-
generated monocyte-derived DCs (moDCs) and CD1c+ mDCs
(Buschow et al., 2010; Schlatzer et al., 2012). The latter study re-
ported 725 proteins expressed in resting and TLR-stimulated
CD1c+ mDCs together, of which the majority (75%) was also
identified, in the present analysis, in resting CD1c+ mDCs, along
with a further 1,500 other proteins. The present dataset thus rep-
resents, to the best of our knowledge, the most complete quan-
titative proteome analysis of human DC subsets and provides a
unique side-by-side comparison of these cells from the same
donors.ween Subsets
4) to visualize possible connections between proteins. (See Table S9.) Proteins
were pointed out by protein data only (see also Experimental Procedures and
ed (based on FA analysis). See also Table S9.
ACa1
Mgea5
Itga4
Arl3
Cd93
Hla-Do
Sirpa
Lrp1
Ormdl3
Cd1c
Siglec9
Casp1
Rhog Cse1lSerpinb9
Itga2b
Ehd1
B
∞-∞
Irf8
 BDCA3 DC-Tr
 BDCA3 DB-tr
 BDCA3 DA-Tr
CD1c DC-Tr
CD1c DB-Tr
CD1c DA-Tr
CD16 DB-Tr
CD16 DA-Tr
CD16 D3-Pr
pDCs DC-Tr
pDCs DB-Tr
pDCs DA-Tr
 BDCA3 D1-Pr
 BDCA3 D3-Pr
 BDCA3 D2-Pr
CD1c D3-Pr
CD1c D2-Pr
CD1c D1-Pr
CD16 D2-Pr
CD16 D1-Pr
CD16 DC-Tr
pDCs D3-Pr
pDCs D2-Pr
pDCs D1-Pr
Merged protein and RNA data
BDCA3 High
C D
15
20
25
30
4 6 8 10 12 14
R = 0.31
HLA-DOB
IDO1
IGF2R
APOL3*
CARD11*
CSRP1*
DBN1*
ERMP1*
FUCA1*
LRRK2*
LZTFL1*
RAB7L1*
RABGAP1L*
CPNE3
SERPINB9
TAP2
ARL3
ARL6IP1
AZU1
CA1
CD93
CHAMP1
EPS15L1
ETV6
GSTM2
HTATSF1
ITGA4
MAN2C1
MAP2K2
MGEA5
NAPG
NSDHL
OTUD6B
PGP
RPL37A
SCYL1
TGM2
YKT6
ZNF326
ALOX5AP
EHD1
ITGA2B
LBR
TOMM40
SIGLEC9
SIRPA
CD101*
CD163*
CD1C*
CTNND1*
SCARB2*
SORT1*
TYROBP*
CA2
CASP1
PPP1R2P3
PRAM1
RTN1
TLR2
C6orf211
GGH
GLRX
LRP1
ORMDL3
VAPB
RHOG
BDCA3 CD1c BDCA3 CD1c
BDCA3
CD1c High
E
lo
g 2
 P
ro
te
in
log2 RNA
Figure 4. Pairwise Comparison of BDCA3+ mDCs and CD1c+ mDCs
(A) Volcano plot depicting protein expression differences (x axis: log2 fold change) and the significance level (y axis: log10 t test p value) as in Figure 1.
(B) Pearson correlation between protein and RNA (microarray) expression levels.
(C) Hierarchical clustering of merged Z-score transcriptome and proteome data of DEPs.
(D and E) Heatmaps of the relative protein expression (LFQ) of proteins identified to be specifically (levels I and III) or differentially (level II or IV; by t test) expressed
in either mDC subset, based on protein and RNA evidence (levels I and II) or protein evidence only (levels III and IV).
See also Figures S1 and S2 and Tables S1, S2, S3, S4, S5, and S6.We report on nearly 400 differentially expressed proteins be-
tween the three main blood DC-like subsets. In addition, despite
the presence of CD1c+ mDCs in the BDCA3+ mDC sample, we
identify over 60 proteins differentially expressed between mDCsubsets, of which we subsequently validated four by flow cytom-
etry. The protein-based signatures we derived provide insight
into possible functional differences between subsets. Although
we cannot discuss in detail all the functional implications of theCell Reports 16, 2953–2966, September 13, 2016 2961
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Figure 5. Confirmation of Differentially Expressed Surface Markers
(A) Representative histogram of the expression of indicated surface markers by specific antibodies (lines) or isotype controls (gray area) on the four subsets.
(B) Bar diagrams summarizing the fluorescence level measured by flow cytometry (FC) in four independent healthy donors (isotype control antibody signal
subtracted; mean ±SEM). All markers were found differentially expressed by one-way ANOVA (p < 0.05) and between pairs of subsets with indicated significance
by post hoc Tukey’s multiple comparison test. *p < 0.05; **p < 0.01; *** < 0.001.
(C) Bar diagrams of mean LFQ values, as obtained by MS analysis (three donors; mean ± SEM).expression differences we have identified, several warrant
further discussion. First, we demonstrate the abundant expres-
sion of the MCM family of proteins in CD1c+mDCs, but not in2962 Cell Reports 16, 2953–2966, September 13, 2016CD16+ monocytes or in pDCs. This protein family is essential
for cell division. Thus, our data support previous findings that,
in contrast to pDCs, a fraction of the blood mDC population
A D F
B
C
E G
Figure 6. Absence of Caspase and Inflammasome Activity in pDCs
(A) Diagrams of LFQ values for caspase-1, as obtained by MS analysis (three donors; mean).
(B and C) Western blot analysis of DC subsets isolated by flow sorting from two independent donors lysed (B) directly after isolation or (C) after overnight
stimulation with R848. Shown are the signals for caspase-1 and actin probed sequentially on one membrane.
(D) Heatmap of log2 intensity values by microarray of probes mapping to inflammasome components (three donors).
(E) Flow cytometry evaluation of surface expression of CD83 on immature or R848/ATP-stimulated (4 hr, 45 min) subsets. Results of a representative donor are
shown.
(F and G) Secretion of indicated cytokines by pDCs and CD1cmDC after stimulation for 4 hr (F) or overnight (G) with R848, followed by 45min with ATP, by ELISA.
Mean values ± SEM from at least four donors. Significance was evaluated by a two-tailed Mann-Whitney test. *p < 0.05; **p < 0.01; ***p < 0.001; ns, non-
significant. See also Figures S3 and S4.may still be able to expand, possibly reflecting an incomplete dif-
ferentiation state (Segura et al., 2012). Our data suggest that, like
pDCs, CD16+ cells may completely lack the potential to expand.
The remaining capacity of mDCs to divide is interesting from a
clinical perspective, as it implies that mDCs after isolation may
have the potential to be further expanded. This concept may
be of interest for the development of immunotherapies for cancer
or chronic inflammatory diseases, where obtaining sufficient cell
numbers is still a major hurdle.
Second, HLA (human leukocyte antigen) molecule expression
demonstrated some marked differences between subsets, sug-
gesting subset-specific antigen presentation. CD1c+ mDCs not
only highly express antigen-presenting CD1c but also more
highly expressed HLA-DQ, as compared to pDCs and CD16+
monocytes (but not HLA-DR). In agreement with a previousreport, BDCA3+ cells uniquely expressed HLA-DO (Hornell
et al., 2006). For these HLA types, either a clear (HLA-DO) or a
unique (HLA-DQ versus HLA-DR) biological function remains to
be defined. Thus, the consequence of this subset-specific
expression remains elusive.
Third, many ER- andGolgi-located proteins were expressed at
higher levels, specifically in pDCs. Previously, it has been shown
that, in mice, pDCs and, to a lesser extent, CD8a+ DCs (the
supposed murine equivalent of BDCA3+ DCs), display a consti-
tutive activation of the unfolded protein response (UPR), as was
indicated by the alternative splicing of XBP1 (Iwakoshi et al.,
2007). The increase in UPR was required for ER expansion to
facilitate rapid IFN-a biosynthesis and is reminiscent of plasma
cell differentiation (Iwakoshi et al., 2007). The high levels of ER
and glycoprotein biosynthesis and transport proteins that weCell Reports 16, 2953–2966, September 13, 2016 2963
describe in pDCs support the paradigm that immature pDCs are
already prepared for rapid IFN-a synthesis. Proteins related to
intracellular protein transport machinery are also overtly ex-
pressed in immature pDCs, and these may provide important
clues to unravel the largely unknown IFN-a secretory route.
From the identified DEPs, we confirmed five cell-surface re-
ceptors by flow cytometry: SIRPa and Siglec-9, which bind to
CD47 and sialic acids, respectively, were found to be highly ex-
pressed on both CD16+ monocytes and CD1c+ mDCs. These
receptors share a capacity to limit DC function and inflammation
and are exploited by bacteria and malignant cells to evade im-
mune responses (La¨ubli et al., 2014; Ohta et al., 2010; Barclay
and Van den Berg, 2014). Lack of these receptors may render
cells insensitive to this evasion. CD1c+ mDCs uniquely ex-
pressed CD163, a scavenger receptor and PRR for bacteria
(Kristiansen et al., 2001; Fabriek et al., 2009). Siglec-10, which
we found selectively expressed on CD16+monocytes, is a puta-
tive adhesion receptor and PRR that has been reported to be ex-
pressed on CD16+ but not CD16 monocytes, as well as on
moDCs (Ancuta et al., 2009; Kivi et al., 2009; Li et al., 2001; Ste-
phenson et al., 2014). Finally, BDCA3+ mDCs highly expressed
CD93, which was reported to mediate phagocytosis and clear-
ance of apoptotic cells and, as such, may act as an accessory
to CLEC9A (Nepomuceno and Tenner, 1998; Norsworthy et al.,
2004).
Our proteome data provided strong evidence for a lack of cas-
pase-1 in pDCs. We validated this by WB and show data to sug-
gest that pDCs have a diminished presence of inflammasome
pathway constituents. Concordantly, pDCs did not respond to
inflammasome activator ATP, while CD1c+ mDCs and CD16+
monocytes did. Our data contradict those of several previous
studies reporting on IL1-b secretion by pDCs (Hurst et al.,
2009; Yu et al., 2010). These studies show pDCs to secrete pico-
grams of IL1b per milliliter of culture supernatant in response to
TLR stimulation alone (without inflammasome activation). How-
ever, this level of IL1b is extremely low compared to production
by CD16+ monocytes, which, we found, can secrete over a 100-
fold more (nanograms of) IL1b per milliliter upon TLR and inflam-
masome stimulation. Furthermore, it is conceivable that traces
(e.g., ±1%) of high IL1b-producing cells may be present in these
pDC preparations isolated by magnetic beads, and such cells
can contribute to the low amount of IL1b found to be secreted.
Interestingly, our proteome data also indicated that, although
expression of caspase-1 was readily detected in the BDCA3+-
enriched samples by proteomics, it was lower than in CD1+
mDCs and CD16+ DCs, a result we also verified using highly
pure cells. Indeed, BDCA3+ mDCs responded less to inflamma-
some activation in the presence of TLR7/8 ligand. This stimulus
matured BDCA3+ mDCs but did not induce cytokine secretion.
However, low IL1-b production by BDCA3+ mDCs relative to
CD1c+ mDCs, in response to the potent BDCA3+ mDC-acti-
vating stimulus poly(I:C), has also been reported (Jongbloed
et al., 2010).
Several recent publications have demonstrated that the pDC
hallmarks type I IFN and IRF7 may directly inhibit IL-1b and in-
flammasome activity (Guarda et al., 2011; Salem et al., 2011).
In pDCs, TLR7 activation by hepatitis C virus induced type I
IFN secretion but induced neither IL-1b nor IL-18. In contrast,2964 Cell Reports 16, 2953–2966, September 13, 2016TLR7 activation in monocytes induced IL-1b and IL-18, rather
than type I IFN (Chattergoon et al., 2014; Dreux et al., 2012).
Thus, the differentiation program involving IRF7 that allows
pDCs to secrete large amounts of Type I IFN may downregulate
inflammasome pathway constituents, including caspase-1.
Although this causal relation still awaits further experimental
confirmation, this could switch the pDC response to TLR stimu-
lation/NF-kB activation away from IL-1b and toward type I IFNs.
A switch between type I IFNs and IL-1b could serve to prevent
excessive damaging inflammation during antiviral responses.
Taken together, the proteome dataset that we describe pro-
vides a rich resource to solidly establish the phenotypic and
functional capacities of human DC subsets and to decipher
the contribution of each subset to the initiation of immune
responses.
EXPERIMENTAL PROCEDURES
Cells
DCs were isolated from apheresis products obtained from healthy volunteers
after written informed consent was obtained and according to institutional
guidelines and overseen by the local institutional review board (Commissie
mensgebonden onderzoek [CMO]). Peripheral blood mononuclear cells
(PBMCs) were purified via Ficoll density gradient centrifugation (Lucron Bio-
products), followed by magnetic-bead (Miltenyi Biotec) or flow-cytometric
isolation, and were directly lysed for MS or WB analysis or were used in
in vitro experiments (see the following text and Supplemental Experimental
Procedures for details).
LC-MS/MS
In brief: Tryptic peptides were analyzed using LC (Easy-nLC; Thermo Fisher
Scientific) coupled to a 7-T linear ion trap Fourier-transform ion cyclotron reso-
nance mass spectrometer model (LTQ FT Ultra, Thermo Fisher Scientific). See
Supplemental Experimental Procedures for details.
MS Data Processing
Proteinswere identified and quantified from rawmass spectrometric files using
MaxQuant software, version 1.3.0.5 (Cox andMann, 2008). A database search
was performed in the Andromeda search engine (Cox et al., 2011) against the
Human Uniprot database (86,749 entries, June 2012). The protein abundance
was determined by MaxLFQ, as described by Cox et al. (2014). The MS prote-
omics data have been deposited to the ProteomeXchange Consortium via
the PRIDE partner repository with the identifier PRIDE: PXD004678 (Vizcaı´no
et al., 2016). (http://proteomecentral.proteomexchange.org). See Supple-
mental Experimental Procedures for details.
Statistical Analysis of Protein and RNA Data
See the Supplemental Experimental Procedures for details. Statistical analysis
was performed in the R programming environment. Data were visualized
using GENE-E software (http://www.broadinstitute.org/cancer/software/
GENE-E) and BioLayout Express3D (version 3.3) (Theocharidis et al., 2009).
For PPI analysis, we used the STRING PPI web tool (version 10; http://
string-db.org/), and FA analysis was done using the DAVID web tool (https://
david.ncifcrf.gov/).
Western Blotting and ELISA
These were performed according to standard procedures. See Supplemental
Experimental Procedures for details and antibodies used.
In Vitro DC Activation
Isolated DC-like subsets were resuspended in X-VIVO 15 (Cambrex) contain-
ing 2% pooled human serum (Sanquin). pDCs were supplemented with
10 ng/ml recombinant human IL-3 (rhIL-3; Cellgenix). Both cell types were
stimulated for 4 hr or overnight with 4 mg/ml R848, followed by 45-min stimu-
lation with 5 mM ATP (Sigma). Culture supernatant was taken for ELISA.
ACCESSION NUMBERS
The accession number for the MS proteomics data reported in this paper is
PRIDE: PXD004678.
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Figure S1 related to figures 1 and 3: Assessment of DC purity by flow cytometry: Flow cytometry results 
for magnetic bead purified subset samples. Displayed for one donor are the side-scatter (SSC) and forward-
scatter (FSC; upper panel) and labelling for indicated subset  identification markers (middle panels) and B 
(CD19) and T (CD3) cell markers (lower panels). For each subset  the sorting gate used to quantify subset 
presence in the sample is marked by a red box. A summary of the percentage  of each subset(of total cells) 
present in the samples from all donors used for MS analysis is given in the table. For BDCA3+ DCs values are 
provided both for total CD11c+BDCA3+ cells (red box) and CD11c+BDCA3hi cells only (dotted red box).  
Please note that for the CD16+ monocyte sample, CD16 itself could not be used to reliably identify CD16+ cells 
after purification because of a decrease of CD16 label likely due to competition between the sorting antibody and 
the staining antibody. Therefore presence of CD16+ monocytes in this sample was based on CD11c only, which 
was justified by the concomitant absence of CD1c+ and BDCA3hi cells.   
 
 
  
E. 
 
 
Figure S2 related to figures 1 and 3: Protein identification and coverage.  
(A-D) Venn Diagrams representing  the proteins identified in each donors for each subsets. (E)The percentage of 
complex components found back in each subset and donor for the indicated 6 essential protein complexes 
retrieved from the CORUM database. Coverage of these complexes provides a measure for the completeness of 
the measured proteome.  
 
 
 
  
 
Figure S3 related to figure 6: Gating strategy for flow sorting of DC-subsets for Western blotting and 
functional analysis. A DC enriched fraction was obtained by magnetic bead depletion of non-DC PBMC 
constituents. This enriched fraction was subsequently sorted using a pool of lineage markers (CD3, CD14, 
CD16, CD19, CD20, and CD56; all excluded), HLA-DR (included) and the subset identification markers 
BDCA1, BDCA3, BDCA4 and CD16.  
 
 
 
 
  
Figure S4 related to figure 6: Additional evidence for the absence of Caspase-1 and Caspase-1 dependent 
cytokine secretion in pDCs. (A) Additional Western blots for Caspase-1 and actin of magnetic bead isolated or 
flow cytometry sorted resting or R848 (ATP) stimulated DC-like subsets from one donor also used for MS 
analysis (donor 2) and 4 additional novel donors (4,5,7,8; Western blots of donors 6 and 9 are depicted in figure 
6 of the main manuscript). (B) Presence of IL-18 in the supernatant of CD1c+ mDCs or pDCs measured by 
ELISA after stimulation for 4 hours with R848 followed by 45 minutes of ATP. Shown is the mean amount 
secreted by 3 donors +/- SEM.    
 
 
 
 Supplemental methods 
 
 
Cells 
For proteome analysis, DCs were isolated from aphaeresis products obtained from healthy volunteers after 
written informed consent and according to institutional guidelines. Peripheral Blood Mononuclear Cells 
(PBMCs) were purified from aphaeresis products via ficoll density gradient centrifugation (Lucron Bioproducts, 
Sint Martens-Latem, Belgium). To obtain peripheral blood leukocytes (PBLs), monocytes were depleted from 
PBMCs via adherence to plastic culture flasks. CD1c+ mDCs and CD16+ mDCs were isolated from PBMCs 
with a CD1c+ DC isolation kit and CD16+ monocyte isolation kit, respectively. BDCA3 myeloid DCs were 
isolated from PBLs by selection for BDCA3+ cells with a CD141 (BDCA3) isolation kit. Plasmacytoid DCs 
were purified from PBLs by positive selection using anti–BDCA-4–conjugated magnetic microbeads (all 
Miltenyi Biotec, Bergisch Gladback, Germany). DC purity was assessed by flow cytometry by staining for 
identification markers as indicated in Figure S1. Antibodies used  for CD11c, CD1c, CD16+, BDCA3,  BDCA2 
and CD123  were all from Miltenyi Biotec and as described previously (Schreibelt et al., 2012; Tel et al., 2013). 
Contamination with T cells and B cells was assessed by double staining of CD19 and CD3 (BD Biosciences). 
For Western blotting and ex vivo stimulation, DCs were isolated from PBMCs obtained from buffy coats of 
healthy donors  after written informed consent and according to institutional guidelines. For these experiments, 
pDCs and CD1c mDCs were either isolated by  flow sorting after an  initial DC-enrichment using a DC-
enrichment kit (Miltenyi Biotec) and subsequent DC-identificationusing Lin1-FITC (BD Biosciences; containing 
a pool of antibodies for CD3, CD14, CD16, CD19, CD20, and CD56; to be excluded) anti-HLA-DR-PE-Cy7 
(positive selection) and anti-BDCA3-APC, anti-BDCA4-PE (B, pDCs) (all from Miltenyi), anti-CD16-APC-Cy7 
(BD Biosciences) and anti-CD1c-PB (Biolegend). See figure S3A for the gating strategy. The four subsets were 
sorted using a FACS Aria II (BD Biosciences).For measuring the subset specific expression of 5 novel selected 
surface markers, PBMCs from healthy donors were stained for each of the surface marker using specific or 
isotype control antibodies  conjugated to PE (below) and either a cocktail containing CD45-APC-Vio770, CD14-
VioGreen, BDCA-3-APC, Clec9a-VioBrightFITC, CD20-PE-Vio770 (all from Miltenyi) CD1c-BV421 
(Biolegend) to identify CD1c mDC (CD45+, CD20-, CD14-, BDCA1+) and BDCA3+ mDC (CD45+, CD20-, 
CD14-, BDCA3+, CLEC9A+), or a cocktail containing CD45-V450 (BD Biosciences), BDCA-2-APC, CD123-
APC-Vio770 (both from Miltenyi), CD16-PE-Cy7, HLA-DR-BV510 and Lin2(CD56, CD3, CD14, CD20, 
CD19)-FITC (all from BD Biosciences) to identify pDCs (CD45+, Lin2-, HLA-DR+, BDCA2+, CD123+) and 
CD16+ monocytes (CD45+, Lin2-, HLA-DR+, CD16+).  Selected novel surface markers were stained using PE-
conjugated monoclonal antibodies against CD93 (Miltenyi Biotec), Siglec-9 (R&D systems), SIRPα 
(Biolegend), CD163 (BD Biosciences) and Siglec-10 (Biolegend).    
 
Protein Extraction/Sample Preparation for MS 
The purified and isolated DC subsets were resuspended in homogenisation buffer (20 mM Hepes (Roche) pH 
7.5, 250 mM sucrose (Baker) and complete protease inhibitor cocktail (Roche)) and disrupted by three cycles of 
freezing and thawing. The cells were centrifuged at 10,000 g to separate soluble and insoluble fractions and 
separated by SDS-PAGE using precasted 4-20% TRIS/Bis ready Gels (Biorad). Both soluble and insoluble 
fractions were loaded onto gels for MS analysis. For each subset in total 8ug of protein was loaded 
corresponding to 5-10.105 cells.  After electrophoreses the protein gel was stained with Novex Colloidal Blue 
(Invitrogen) and each lane was cut in to ten fractions. Gel fractions were subsequently treated with dithiothreitol 
(DTT) and iodoacetamide and digested by trypsin.  Digested samples were acidified to a final concentration of 
0.5% HAc and purified by STAGE tips as described before (Rappsilber et al., 2003). 
 
Liquid chromatography tandem mass spectrometry 
All the samples were analyzed using liquid chromatography (Easy n-LC; Thermo Fisher scientific) coupled to a 
7-T linear ion trap Fourier-Transform ion cyclotron resonance mass spectrometer model (LTQ FT Ultra, Thermo 
Fisher Scientific). Chromatography was performed with PicoTip columns (New Objective, Woburn, USA) of 15 
cm 100 µm in size and was packed with 3 µm Reprosil C18 beads (Dr. Maisch). Tryptic peptides were separated 
using a 90 min gradient from 12% buffer B to 40 % buffer B (buffer B contains 80% acetonitrile in 0.5% acetic 
acid) with a flow-rate of 300 nL/min. The LTQ-FT instrument was operated in data-dependent mode. Full-scan 
MS spectra of intact peptides (m/z 350-1500) with an automated gain control accumulation target values of 
1.000.0000 ions were acquired in the Fourier transform ion cyclotron resonance cell. The four most abundant 
ions were sequentially isolated and fragmented in the linear ion trap by applying collisional induced dissociation 
using an accumulation target value of 10.000, a capillary temperature of 100 ° C, and a normalized collision 
energy of 27%. A dynamic exclusion of ions previously sequenced was enabled. All unassigned charges states 
and singly charges ions were excluded from sequencing. A minimum of 200 counts was required for MS2 
selection. Maximum injection times were set at 500 ms and 400 ms respectively for FT MS and IT MS/MS 
measurements. 
 
Mass spectrometry data processing and protein identification 
Proteins were identified and quantified from raw mass spectrometric files using MaxQuant software version 
1.3.0.5 (Cox and Mann, 2008). Peak lists were generated to contain the six most intense peaks per 100 Dalton 
mass window. Database search was performed in Andromeda search engine (Cox et al., 2011) against Human 
Uniprot database (86,749 entries, June 2012) supplemented with sequences of contaminant proteins. We 
included cysteine carbamidomethylation as a fixed modification and oxidized-methionine and protein N-terminal 
acetylation as variable modifications. The minimum peptide length was six amino acids and up to two tryptic 
mis-cleavages were considered for identification. The time window of 2 minutes was allowed to match peptides 
across different LC-MS/MS run from each fraction on basis of mass and retention time. At least two peptides, of 
which one was unique, were required for the protein identification. Protein quantification was based on both 
unique and “razor” peptides. The protein abundance was determined by MaxLFQ that is based on comparison of 
individual peptide intensities over all samples as described by (Cox et al., 2014) and LFQ intensities values were 
normalized across biological replicates using median value. For ANOVA and hierchical clustering (below) 
missing values were filled by random values from the lower end of the expression value spectrum using Perseus 
software (version 1.4.2.23; Tyanova et al., 2016). Raw MS data are available at proteome central (accession 
number PXD004678) (http://proteomecentral.proteomexchange.org) 
 
Statistical analysis of protein data 
Since DC subsets derived from the third donor were of lower purity further use of these samples is only justified 
when sufficiently stringent criteria are used. Therefore, to extract reliable and informative data, observed protein 
expression differences were only used when present in at least two out of three donors or when confirmed by 
additional data from independent studies. 
The list of differentially expressed proteins for hierarchical clustering and signature generation was obtained by 
merging subsets specifically expressed proteins (present in at least 2 out of 3 donors and absent in all other 
subsets in all donors) to proteins that were called significantly differentially expressed by 3-group one-way 
ANOVA (p-0.05) on the imputation supplemented protein data. On the ANOVA p-values a bonferoni-Holms 
correction for multiple testing was performed (Table S7). Furthermore, to prevent false positive results, proteins 
expressed below a measured LFQ value of 217 were excluded from ANOVA because for these proteins the 
imputed LFQs to fill missing values may exceed that of the measured values. ANOVA was performed in the R 
programming environment.   
 
Data processing of publically available transcriptome data 
The raw microarray data (CEL files) were downloaded from ArrayExpress (accession: E-TABM-34) for human 
DC subsets (pDCs, BDCA3+ DCs, CD1c+ DCs, CD16+ cells). The raw data was normalized using the RMA 
normalization function of the affy package and mapped using hgu133plus2.db annotation package (Gautier et al., 
2004). After data normalization, only the genes that had an expression level above background in at least 1 out of 
4 populations with a differential expression between at least 2 cell types were considered. In cases where 
multiple probes were related to a gene, only the probe expressed highest across all samples was considered. 
 
RNA sequencing  
For RNA sequencing RNA was extracted from subsets lysed immediately after harvesting in Trizol reagent 
(Thermo fisher) and forcing the lysate trough a 25 gauge syringe for 10 times.  RNA was subsequently isolated 
using and RNeasy kit and on-column DNase treatment ( both from Qiagen). Thereafter for each sample 250 ng 
of total RNA was treated by Ribo-Zero rRNA Removal Kit (epicentre) to remove ribosomal RNAs (according to 
manufacturer instructions) and mRNA was purified using the (Zymo research). Subsequently purified RNA was 
fragmented using (5x) fragmentation buffer (200 mM Tris acetate pH 8.2, 500 mM potassium acetate and 150 
mM magnesium acetate) and incubated at 95°C for 90 seconds. After a new round of purification, first strand 
cDNA was synthesized from fragmented RNA with SuperscriptIII (Invitrogen). First strand cDNA was purified 
by MinElute cleanup kit (Qiagen) and second strand cDNA was prepared in the presence of dUTP instead of 
dTTP and using random hexamers. Double stranded cDNA was purified by Qiagen mini elute columns and used 
for Illumina sample prepping and sequenced according to the manufacturer’s instructions. The RNAseq reads 
were mapped to HG18 and used to calculate RPKM values (reads per kilobase of gene length per million reads) 
(Mortazavi et al., 2008). 
Hierarchical clustering 
The hierarchical clustering of samples and genes was performed based on 1-Pearson correlation in combination 
with average linkage clustering using GENE-E software (http://www.broadinstitute.org/cancer/software/GENE-
E).Proteome and transcriptome data were mapped based on similarity of the gene symbol. Both datasets were 
separately normalized and z-scored in the R programming environment (mean to 0 and variance to 1). From the 
merged dataset differentially expressed proteins we extracted (present in at least 2 out of 3 donors and absent in 
all other subsets in all donors plus proteins called significantly differentially expressed by 3-group one-way 
ANOVA (p-0.05).  The thus obtained dataset was used for hierarchical clustering of samples.  
 
Signature generation 
For proteins highly or lowly expressed in each of the 3 subsets (pDCs, CD1c+ mDC, CD16+ monocytes), 
protein signatures were generated by combining protein and transcriptome data in 4 levels of evidence according 
to the criteria below (Table S7).  
For the high expression signatures for each subset the criteria were:  
Level I) specific proteins with RNA support. Protein: Is specifically expressed in the subset in 3 out of 3 donors 
but absent in all other subsets. RNA: MinMax >1.5 fold for linear values (for Log2 values, FC = Log2(Min)cluster-
subset(s)-Log2(Max)other subsets> 0.58). Proteins specifically expressed only in 2 out of 3 donors were “rescued” and 
included in the signatures because of RNA support (MinMax >1.5 fold).  
Level II) differentially expressed proteins with RNA support. Protein: 3-group one-way ANOVA proteomics 
with multiple testing correction (BH) <0.05 and expression in the subset(s) in at least 2 out of 3 donors. Post-hoc 
t-test comparisons proteomics for the high expressing subset(s) against other subset p<0.05 and a fold change of 
>2. RNA: MinMax >1.5 fold for linear values. ANOVA significant proteins (p<0.05) lost by multiple testing 
correction but meeting all other criteria and supported by RNA expression (MinMax >1.5 fold) were included in  
Table S7 as low confidence DEPs. 
Level III) Specific protein expression without RNA support. Protein: As level I. RNA: Criteria Level I are not 
met or no data available. Proteins specifically expressed in only 2 out of 3 donors were also included Table S7 as 
low confidence DEPs 
Level IV) Differential protein expression without RNA support. Protein as in level II; RNA: Conditions level II 
are not met or no data available. 
 
For the proteins lowly expressed in subset the criteria were as above with the following modifications:  
Level I) Protein: Absent in the cluster-subset but present in all other subsets; RNA: Minimum expression in other 
subsets over maximum in the subset > 1.5 fold. Proteins absent in the cluster-subset in 3/3 donors but present in 
only 2/ 3 donors in (any of) the other subsets are  
included in Table S7 as low confidence DEPs. 
Level II) Protein: Presence in the other subset in at least 2 out of 3 donors.  
Level III) Protein as for level I. Proteins absent in the cluster-subset in 3/3 donors but present in only 2/ 3 donors 
in (any of) the other subsets were also included in Table S7 as low confidence DEPs. 
Level IV) Protein as for level II. RNA: Did not meet criteria level II or no data available.  
 
Finally, proteins identified in at least two donors in one subset but not identified as differentially expressed 
according to the signature criteria above, yet found differntially expressed based on RNA expression data are 
given in supplementary table S8.    
 
Extracting DEPs between BDCA3+ mDCs and CD1c+ mDCs:  
To extract DEPs we aplied roughly the same structure as for signature generation but now based on t-tests and 
with the follwing specific rules: 
Level I: present in > 2/3 donors in one of the 2 subsets, no presence in the other subset (3/3), also significant at 
RNA level by Min Max (> 1.5 fold) 
Level II: t-test significant (p-value <0.05, FC >2), also significant at RNA by Min max (> 1.5 fold) 
Level III: present in > 3/3 donors in one of the 2 subsets, no presence in the other subset (3/3), no RNA data or 
significance. Proteins only specifically present in 2/3 donors are only present in Table S7 as low confidence 
DEPs 
Level IV: t-test significant (p-value < 0.01, FC>2); no presence in the other subset (3/3), no RNA data or 
significance. Proteins with a t-test p-value between 0.01 and 0.05 are only present in Table S7 as low confidence 
DEPs 
 
Protein-protein Interaction, GO and pathway analysis  
Signatures depicted in figure 2 were used as input for protein-protein interaction (PPI) analysis using the 
STRING PPI web tool (http://string-db.org/; version 10). A confidence score of 0.4 was used as a cut-off for 
protein-protein interaction allowing all sources of evidence. Obtained confidence scores for each interaction can 
be found in table S9. The generated interaction networks were uploaded in Biolayout express 3D (version 3.3) 
for graphical representation  (Theocharidis et al., 2009). Signatures were mapped onto functional categories 
using the functional annotation clustering algorithm in the DAVID web tool (https://david.ncifcrf.gov/) using 
standard settings. Full functional annotation output can be found in Table S9.  
 
Western blotting  
Reduced cells lysates were loaded on a 10% SDS-gel and transferred to a PVDF membrane. Caspase-1 was 
stained with the caspase-1-p10 (C-20): sc-515 antibody (Santa Cruz Biotechnology) and Actin with anti-Actin 
(20-33) antibody (Sigma). Blots were analyzed on the Odyssey imaging system. 
 
ELISA 
Cytokine production of IL-1β (R&D Systems) and TNF (eBioscience) was measured by ELISA. IL-18 
production was analyzed by using Luminex. To monitor activation, cells were stained for 30 minutes with anti-
CD83-FITC (BD Biosciences)  and analyzed by flow cytometry. 
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Overview of supplemental Tables: 
 
Table S1: Correlation between biological and technical replicates_related to figures 1 and 4 
Tab1: Technical replicates 
Tab2: biological replicates 
Table S2: Identified proteins_related to figures 1 and 4: Protein table of all proteins identified in all 4 subsets 
and all 4 donors (at least 2 in one subsets, no LFQ restrictions) 
Table S3: Identified peptides_related to figures 1 and 4: Peptide table of all peptides identified in all 4 subsets in 
all 4 donors 
Table S4: Pairwise comparison of subsets_related to figures 1 and 4: t-test of all combinations of all 4 subsets 
Table S5: RNA sequencing data donor 2_related to figures 1 and 4 
Table S6: Merged RNA and protein data_related to figures 1 and 4 
Tab1: merged table RNA and protein data  (MA and RNA seq)  
Tab2: correlation of RNA (MA and RNA seq)  
Table S7: Signatures_related to figures 2 and 4: Signatures for all 6 groups in the 3 subset comparison and for 
BDCA3 compared to CD1c+ mDC  
Tab1: pDC vs CD1c & CD16 up 
Tab2: pDC vs CD1c & CD16 down  
Tab3: CD1c vs pDC& CD16 up 
Tab4: CD1c vs pDC% CD16 down 
Tab5: CD16vs pDC&CD1c up 
Tab6: CD16 vs pDC&CD1c down 
Tab7: BDCA3 vs CD1c up 
Tab8: CD1c vs BDCA3 up 
Table S8: Table S8_DEGs not confirmed by proteomics_related to figure 2 and 4  
Tab1: pDC vs CD1c & CD16 up 
Tab2: pDC vs CD1c & CD16 down  
Tab3: CD1c vs pDC& CD16 up 
Tab4: CD1c vs pDC% CD16 down 
Tab5: CD16vs pDC&CD1c up 
Tab6: CD16 vs pDC&CD1c down 
Tab7: BDCA3 vs CD1c up 
Tab8: CD1c vs BDCA3 up 
Table S9: PPI and FA analysis_ related to figure 3 
Tab1: pDC vs CD1c & CD16 up 
Tab2: pDC vs CD1c & CD16 down  
Tab3: CD1c vs pDC& CD16 up 
Tab4: CD1c vs pDC% CD16 down 
Tab5: CD16vs pDC&CD1c up 
Tab6: CD16 vs pDC&CD1c down 
Tab7: BDCA3 vs CD1c up 
Tab8: CD1c vs BDCA3 up 
 
 
 
